1 February 202 GSK plc (NYSE:GSK) delivers strong 2022 performance with full year sales of £29.3 billion。
+19% AER, +13% CER; Total EPS 371.4p >100%
Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations。
Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions。
Specialty Medicines £11.3 billion +37% AER, +29% CER; HIV +20% AER, +12% CER; Oncology +23% AER, +17% CER; Immuno-inflammation and other specialty +29% AER +20% CER; COVID-19 solutions (Xevudy) sales £2.3 billion。
Vaccines £7.9 billion +17% AER, +11% CER; Shingrix £3 billion +72% AER, +60% CER。
Total continuing operating margin 21.9%. Total EPS 371.4p > 100% primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business. Total continuing EPS 110.8p +34% AER, +18% CER。
Adjusted operating margin 27.8%. Adjusted operating profit growth +26% AER, +14% CER. This included a decline in growth from COVID-19 solutions of approximately 3% AER and CER。
General Medicines £10.1 billion +5% AER, +1% CER。
Adjusted EPS 139.7p +27% AER, +15% CER. This included a decline in growth from COVID-19 solutions of approximately 4% AER, 3% CER。
Full-year 2022 cash generated from operations attributable to continuing operations £7.9 billion. Full-year free cash flow £3.3 billion。
2023 guidance
Turnover is expected to increase between 6 to 8 perent。
Adjusted operating profit is expected to increase between 10 to 12 per cent。
Adjusted earnings per share is expected to increase between 12 to 15 per cent。
About GSK plc (LSE/NYSE:GSK)
GSK plc (LSE/NYSE:GSK) is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.